BusinessOcera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with CirrhosisBy Nasdaq OMXJan 5, 2017, 2:05 PM UTC
BusinessOcera to Present at the Ladenburg Thalmann 2nd Annual Healthcare ConferenceBy Nasdaq OMXSep 20, 2016, 1:10 PM UTC
